Introduction
============

Oral carcinomas are the sixth most common cancers in the world, after cancers of the lung, breast, colorectal, prostate and gastric cancers [@B1]. Squamous cell carcinoma (SCC) of the hypopharynx is less prevalent than at most other major sites of the head and neck, such as the oral cavity, larynx and oropharynx, and accounts for approximately 3% to 5% of all head and neck SCC [@B2],[@B3]. Hypopharynx SCCs have their own specific and unique characteristics and considerations regarding treatment. Although the incidence of distant metastasis in hypopharynx SCC is low compared to other cancer types, such as breast or lung cancer, distant metastasis is a major determinant of management and prognosis. Treatment algorithms for hypopharynx SCC have been based on a multitude of factors including tumor characteristics (histology, biology and stage) and patient characteristics (co-morbidity and performance status). Despite evolution in management, the overall survival of patients with distant metastases has not improved significantly during the past 20 years [@B4].

Site and burden of distant metastatic disease are interesting, easy to assess clinical markers that can help triage patients into good and poor prognosis categories. Moreover, specific clinical patterns of distant metastasis can be linked to some baseline epidemiological and clinical factors as well as biologic and molecular factors. Population based databases can be utilized to answer many of the above questions. As far as we know, studies describing the clinical correlates and prognostic value of distant metastases in hypopharynx SCC systematically are few and we sought to explore prevalence and prognostic impact of synchronous distant metastases among patients with hypopharynx SCC in this study.

Materials and Methods
=====================

Cohort population
-----------------

The SEER program is the largest publicly available cancer dataset, which contains data on patient demographics, tumor characteristics, first course of treatment, and follow-up information. However, SEER does not currently include any information on location of metastases in the standard research data until 2010. The criteria defined for inclusion in this study were primary histologically confirmed hypopharynx SCC and diagnosed between 2010 and 2014. We excluded a total of 244 patients mainly because of unknown pathology type of tumor, lack of racial information, unstaged tumors or \'blanks\' metastatic site. A total of 1780 hypopharynx SCC patients were included in the final sample for this analysis.

Statistical analysis
--------------------

The patients\' demographic and tumor characteristics were summarized with descriptive statistics. We examined the relationship between these factors and distant metastases using Chi-squared tests.

Survival was defined as the number of months between the date of diagnosis and the date of death of any causes (OS) or of their cancer (CSS). For analysis of overall survival, the time from diagnosis until the end of the follow-up was used together with the information whether a patient died or not. For cancer-specific survival, CSS was calculated from the date of diagnosis to the date of cancer specific death whereas other deaths unrelated to hypopharynx SCC were censored. The censoring was based on the coding of these endpoints in the SEER database (alive, cancer-associated death, other death). We evaluated the association between survival and different variables using the methods of Kaplan-Meier. Univariate analysis was performed using the log-rank test. Multivariate analyses with the Cox proportional hazards model were used to test the independent significance of the predictors.

Two-sided *P* value \< 0.05 was considered statistically significant and confidence intervals (CIs) were set as 95%. All of statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL).

Results
=======

Clinical Characteristics of all Patients
----------------------------------------

Among the 1780 patients, there were 1452 males (81.6%) and 328 females (18.4%). Median age was 64, with a range of 25-95. About 4.9% tumors were well differentiated (Grade I), while 51.1% were moderately differentiated (Grade II) and 44.0% were poorly differentiated or undifferentiated (Grade III). 62.2% (n=1107) of the patients were stage IV (Figure [1](#F1){ref-type="fig"}).

According to the 7th edition of UICC/AJCC Staging System, 197 patients (11.1%) were T1, 619 patients (34.8%) were T2, 459 patients (25.8%) were T3, 341 patients (19.2%) were T4a, and 164 patients (9.2%) were T4b. With regard to N classifications, 606 patients (34.0%) were N0, 309 patients (17.4%) were N1, 76 patients (4.3%) were N2a, 428 patients (24.0%) were N2b, 282 patients (15.8%) were N2c, and 79 patients (4.4%) were N3. Patients\' characteristics are listed in Table [1](#T1){ref-type="table"}. Patients with pyriform sinus carcinoma was almost half of all patients (49.9%) when diagnosed.

Metastasis pattern
------------------

The database only had metastatic information related to liver, lung, bone and brain metastasis. In the patients of all-stage hypopharynx SCC, the most frequent site of synchronous distant metastases at initial diagnosis was lung (n=72), followed by liver (n=19) and bone (n=18). Metastasis to brain (n=6) was the least among the four sites.

As shown in Table [2](#T2){ref-type="table"}, histological grade of tumor was found to be independently associated with lung metastases and poorer differentiation was an independent prognostic parameter for higher incidence of lung metastasis (p=0.001). In addition, we found that T classification was also an independent parameter for metastatic diseases. A higher T category was associated with higher incidence of lung, bone and brain metastasis (p=0.004, p\<0.001 and p=0.010, respectively). The same results were found in N category in lung and bone metastasis (p\<0.001 and p=0.019, respectively).

What\'s more, lung metastatic diseases were associated with Caucasian and male gender (p=0.013 and p=0.024, respectively). Pyriform sinus carcinoma was associated with lower incidence of liver metastasis (p=0.041).

Survival
--------

The median follow-up time was 13.0 months, with a range from 0 month to 59.0 months. For patients alive at the end of follow-up, the median follow-up time was 19.0 months, with a range from 0 month to 59 months. Since the time of follow-up is short in current study, we only estimated the 1-year OS and CSS for patients with different metastases. The 1-year OS was 33.4%, 17.1%, 18.5% and 16.7% for patients with lung, liver, bone and brain metastasis, respectively. The 1-year CSS was 32.3%, 17.6%, 12.5% and 33.3% for patients with lung, liver, bone and brain metastasis, respectively.

On univariate analysis, age, race, tumor location, T classification, N classification, distant metastases and surgery therapies to the primary tumor could influence OS and CSS among patients with hypopharynx SCC (Table [3](#T3){ref-type="table"}).

Multivariate models controlling for different variables demonstrated that age, race, tumor location, T classification, N classification, distant metastases and surgery therapies to the primary tumor were independent prognostic factors of OS and CSS (Table [4](#T4){ref-type="table"}). Elderly patients with higher T category, higher N category, posterior wall of hypopharynx cancers, multiple sites of metastases and no surgery therapies to the primary tumor were more likely to reduce life expectancy.

In our study, 5-year overall survival are 53.1% and 29.2% for localized and regional hypopharynx SCC patients, respectively, which are much higher than metastatic hypopharynx SCC patients (24.6%). The same results were found in CSS (Figure [2](#F2){ref-type="fig"}).

Discussion
==========

The current analysis has pointed out some interesting correlations between some baseline criteria and the patterns of distant metastases. For example, lung metastatic diseases were associated with male gender and maybe the lifestyles (smoking and alcohol drinking) could partly explain the observed sex-based differences. Most patients when diagnosed have advanced-stage disease and 81.97% of the patients have stage III or IV disease at presentation (Figure [1](#F1){ref-type="fig"}), which were consistent with many other studies [@B4]-[@B6]. Higher T categories are observed in patients presenting with M+ disease as opposed to M0 and advanced regional disease (N3 disease) increased the risk of distant metastases.

Moreover, in current study, tumor location is another risk factor for distant metastatic diseases. Lesions of the hypopharynx are subdivided into the aryepiglottic fold, pyriform sinus, and posterior hypopharyngeal wall by anatomical location [@B7],[@B8]. The incidence of postcricoid carcinoma was low (3.5% in our study). Most postcricoid tumors were advanced pyriform fossa tumors. Therefore, postcricoid tumors were amalgamated with two or three wallapex tumors of the pyriform fossa. Pyriform sinus carcinoma was associated with lower incidence of liver metastasis (p=0.041) and patients with lateral wall disease had higher survival than patients with posterior wall cancers (p \<0.001).

We found higher rates of synchronous distant metastases due to the development of diagnostic techniques. In autopsy findings, lung, liver and bone were the most frequent sites of distant metastases and no brain metastasis was found [@B9],[@B10]. What is different is that distant metastases were much more common when autopsy due to the inclusion of metastases after treatment, for example, the highest autopsy distant metastatic rate was 60% in tumors of the hypopharynx [@B11] but the patterns of metastases were similar.

Compared with colorectal cancer [@B12] and breast cancer [@B13], prognosis of metastatic hypopharynx SCC is always dismal [@B14], which is not so much due to malignant biological behaviors of hypopharynx SCC as to lack of effective systemic treatment. What\'s worse, for metastatic hypopharynx SCC patients, this a bit less definitively since often treated with combination chemoyherapy, evidence for survival benefit cetuximab, advent of nivolumab 2nd line.

In our study, number of metastatic sites was an independent prognostic parameter both for OS and CSS. Many studies have indicated that patients with oligometastases may benefit from local aggressive therapy and increase their life expectancy [@B15]. However, absence of information about performance status of the patients in the current analysis should be taken into account when interpreting these findings as differences in baseline performance may have led to selection bias in the choice of local treatments (i.e. patients with better performance status are being referred to surgery more likely than patients with unfavorable performance status). What\'s more, there is a selection bias of oligometastatic disease, which indeed surgeons have been operating primaries in patients with low M+ burden, versus extensive metastatic disease, and this bias is hard to filter out. In addition, benefits of surgery of the primary tumor in cases of a metastatic solid tumor have been suggested for a number of solid tumors including metastatic pancreatic adenocarcinoma and neuroendocrine tumors and metastatic hepatocellular carcinoma [@B15]-[@B18]. This strategy is currently being evaluated in a number of ongoing studies for metastatic breast cancer [@B19],[@B20].

Furthermore, early diagnosis and treatment is of particular importance. In our study, 5-year overall survival are 53.1% and 29.2% for localized and regional hypopharynx SCC patients, respectively, which are much higher than metastatic hypopharynx SCC patients (24.6%). The same results were found in CSS (Figure [2](#F2){ref-type="fig"}).

Better understanding of clinical correlates and prognostic value of distant metastases is helpful in the clinical decision-making process. Since lung is the most frequent site of distant metastases, contrast enhancement computed tomography (CT) on chest should be maintained according to NCCN guideline [@B21]. And for patients with high risk factors of specific site of metastasis, imaging of other sites should be applied. Diagnosis of metastasis is essential not only for staging, but also for further systematic treatment. With the development of medical technology, quantities of therapy methods, including surgery and stereotactic body radiotherapy (SBRT), have been applied to clinical practice for metastases sites and proved to be effective [@B15].

As far as we know, this is the first SEER analysis assessing clinical correlates and prognostic value of distant metastases in a large cohort of patients with hypopharynx SCC. However, there are still some limitations. Firstly, the details about metastases, such as sizes and exact metastatic lesion quantity in specific organ, were not included. Secondly, it is lack of information about systemic therapy options the patients have received. The use of chemoradiotherapy for the purpose of organ preservation has been increasing [@B4],[@B22]-[@B24], especially in recent years, but SEER does not currently include any information in the standard research data. Thirdly, all information on metastases is from their first diagnosis and lack of following information, including treatment modalities of the patients which may confound the assessment of overall survival analysis. Thus, cancer-specific survival has been evaluated as a primary outcome in this study to avoid the confounding effect of non-cancer deaths.

Conclusion
==========

In the patients of hypopharynx SCC, lung was the most frequent site of distant metastases. Poorer prognosis was associated with elderly patients, higher T category, advanced N category, posterior wall of hypopharynx cancers, no surgery therapies to the primary tumor and more metastatic sites.
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###### 

Patients\' characteristics.

                                       number of patients   \%
  ------------------------------------ -------------------- ------
  Age                                                       
  Median                               64                   
  Range                                25-95                
  Gender                                                    
  Male                                 1452                 81.6
  Female                               328                  18.4
  Race                                                      
  Caucasian                            1378                 77.4
  Asian                                117                  6.6
  African American                     285                  16.0
  T classification                                          
  T1                                   197                  11.1
  T2                                   619                  34.8
  T3                                   459                  25.8
  T4a                                  341                  19.2
  T4b                                  164                  9.2
  N classification                                          
  N0                                   606                  34.0
  N1                                   309                  17.4
  N2a                                  76                   4.3
  N2b                                  428                  24.0
  N2c                                  282                  15.8
  N3                                   79                   4.4
  Grade                                                     
  1                                    88                   4.9
  2                                    909                  51.1
  3                                    783                  44.0
  Surgery therapy                                           
  Yes                                  451                  25.3
  No                                   1329                 74.7
  Tumor location                                            
  Pyriform sinus                       889                  49.9
  Postcricoid region                   63                   3.5
  Aryepiglottic fold, hypopharyngeal   141                  7.9
  Posterior wall of hypopharynx        134                  7.5
  Overlapping lesion of hypopharynx    58                   3.3
  Hypopharynx, NOS                     495                  27.8

Abbreviations: NOS: not otherwise specified

###### 

Demographic and clinical features of patients with and without metastases

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Features                             Lung Metastasis   P\      Liver Metastasis   P\      Bone Metastasis   P\      Brain Metastasis   P\                           
                                                         value                      value                     value                      value                        
  ------------------------------------ ----------------- ------- ------------------ ------- ----------------- ------- ------------------ ------- --------- ------ --- -------
  Gender                                                         0.024                                        0.999                              0.618                0.600

  Male                                 1386              66                         1436    16                        1436               16                1446   6   

  Female                               322               6       325                3       326               2                          328     0                    

  Age                                                            0.558                                        0.764                              0.865                0.969

  ≤64                                  865               39                         895     9                         894                10                901    3   

  \>64                                 843               33                         866     10                        868                8                 873    3   

  Race                                                           0.013                                        0.327                              0.767                0.034

  Caucasian                            1332              46                         1366    12                        1365               13                1376   2   

  Asian                                111               6                          115     2                         116                1                 116    1   

  African\                             265               20                         280     5                         281                4                 282    3   
  American                                                                                                                                                            

  Grade                                                          0.001                                        0.191                              0.615                0.149

  1                                    87                1                          88      0                         88                 0                 88     0   

  2                                    885               24                         902     7                         899                10                908    1   

  3                                    736               47                         771     12                        775                8                 778    5   

  T classification                                               0.004                                        0.280                              \<0.001              0.010

  T1                                   196               1                          195     2                         195                2                 197    0   

  T2                                   595               24                         611     8                         616                3                 618    1   

  T3                                   442               17                         457     2                         457                2                 457    2   

  T4a                                  325               16                         338     3                         337                4                 341    0   

  T4b                                  150               14                         160     4                         157                7                 161    3   

  N classification                                               \<0.001                                      0.221                              0.019                0.211

  N0                                   601               5                          602     4                         604                2                 606    0   

  N1                                   295               14                         306     3                         301                8                 308    1   

  N2a                                  74                2                          75      1                         76                 0                 76     0   

  N2b                                  402               26                         424     4                         425                3                 424    4   

  N2c                                  265               17                         278     4                         279                3                 281    1   

  N3                                   71                8                          76      3                         77                 2                 79     0   

  Tumor location                                                 0.271                                        0.041                              0.629                0.884

  Pyriform sinus                       853               36                         886     3                         881                8                 885    4   

  Postcricoid region                   62                1                          62      1                         62                 1                 63     0   

  Aryepiglottic fold, hypopharyngeal   139               2                          138     3                         141                0                 141    0   

  Posterior wall of hypopharynx        130               4                          131     3                         132                2                 134    0   

  Overlapping lesion of hypopharynx    54                4                          56      2                         58                 0                 58     0   

  Hypopharynx, NOS                     470               25                         488     7                         488                7                 493    2   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NOS: not otherwise specified

###### 

Univariate analysis of OS and CSS in hypopharynx SCC patients

  Prognostic factor                    1-y overall survival   1-y cancer-specific survival          
  ------------------------------------ ---------------------- ------------------------------ ------ ---------
  Gender                                                      0.253                                 0.117
  Male                                 67.2                                                  69.6   
  Female                               68.1                                                  74.1   
  Age                                                         \<0.001                               0.004
  ≤64                                  72.2                                                  73.7   
  \>64                                 62.4                                                  65.4   
  Race                                                        \<0.001                               \<0.001
  Caucasian                            69.9                                                  73.2   
  Asian                                66.8                                                  72.8   
  African American                     55.5                                                  56.1   
  Grade                                                       0.937                                 0.996
  1                                    65.8                                                  69.5   
  2                                    67.4                                                  70.7   
  3                                    67.5                                                  70.1   
  T classification                                            \<0.001                               \<0.001
  T1                                   85.8                                                  89.8   
  T2                                   74.6                                                  77.0   
  T3                                   63.1                                                  69.6   
  T4a                                  58.5                                                  60.3   
  T4b                                  50.0                                                  52.3   
  N classification                                            \<0.001                               \<0.001
  N0                                   72.3                                                  80.4   
  N1                                   68.8                                                  71.4   
  N2a                                  65.3                                                  71.5   
  N2b                                  67.8                                                  73.2   
  N2c                                  59.7                                                  56.5   
  N3                                   50.6                                                  51.0   
  Tumor location                                              \<0.001                               0.002
  Pyriform sinus                       72.0                                                  74.4   
  Postcricoid region                   66.1                                                  74.9   
  Aryepiglottic fold, hypopharyngeal   77.4                                                  78.3   
  Posterior wall of hypopharynx        59.7                                                  59.0   
  Overlapping lesion of hypopharynx    58.3                                                  62.6   
  Hypopharynx, NOS                     59.5                                                  64.2   
  Surgery therapy                                             \<0.001                               \<0.001
  Yes                                  78.6                                                  82.5   
  No                                   63.6                                                  67.4   
  Distant metastases                                          \<0.001                               \<0.001
  No                                   69.5                                                  73.1   
  Single                               32.0                                                  30.8   
  Multiple                             22.1                                                  21.4   

Abbreviations: NOS: not otherwise specified

###### 

Impact of prognostic factors for OS and CSS by multivariate analyses.

  Prognostic factor                    overall survival   cancer-specific survival                                     
  ------------------------------------ ------------------ -------------------------- ----------- ------ -------------- -----------
  Age                                  0.00               1.55                       1.36-1.78   0.00   1.44           1.20-1.73
  Race                                 0.00                                                      0.00                  
  Caucasian                                               1(reference)                                  1(reference)   
  Asian                                                   1.07                       0.81-1.41          0.93           0.64-1.35
  African American                                        1.47                       1.24-1.75          1.40           1.12-1.75
  T classification                     0.00                                                      0.00                  
  T1                                                      1(reference)                                  1(reference)   
  T2                                                      1.67                       1.23-2.25          2.10           1.29-3.41
  T3                                                      2.34                       1.72-3.18          2.99           1.84-4.86
  T4a                                                     3.32                       2.43-4.54          4.46           2.73-7.29
  T4b                                                     3.21                       2.28-4.53          4.19           2.49-7.05
  N classification                     0.01                                                      0.00                  
  N0                                                      1(reference)                                  1(reference)   
  N1                                                      1.05                       0.86-1.29          1.16           0.85-1.57
  N2a                                                     1.25                       0.87-1.78          1.53           0.97-2.43
  N2b                                                     1.12                       0.93-1.35          1.30           1.00-1.69
  N2c                                                     1.17                       0.95-1.43          1.64           1.25-2.17
  N3                                                      1.82                       1.33-2.48          2.44           1.65-3.61
  Tumor location                       0.00                                                      0.02                  
  Pyriform sinus                                          1(reference)                                  1(reference)   
  Postcricoid region                                      1.46                       1.02-2.11          1.57           0.94-2.64
  Aryepiglottic fold, hypopharyngeal                      1.03                       0.78-1.36          0.86           0.57-1.29
  Posterior wall of hypopharynx                           1.37                       1.07-1.76          1.51           1.08-2.10
  Overlapping lesion of hypopharynx                       1.15                       0.77-1.71          1.31           0.80-2.15
  Hypopharynx, NOS                                        1.29                       1.10-1.51          1.30           1.06-1.60
  Surgery therapy                      0.00               1.45                       1.23-1.70   0.00   1.51           1.19-1.93
  Distant metastases                   0.00                                                      0.00                  
  No                                                      1(reference)                                  1(reference)   
  Single                                                  2.24                       1.71-2.93          2.36           1.68-3.31
  Multiple                                                2.74                       1.60-4.70          2.87           1.59-5.16

Abbreviations: CI = confidence interval; HR = hazard ratio; P values were calculated using an adjusted Cox proportional-hazards model
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